10th March 2020
The tumour microenvironment: Key to controlling cancer cell growth Research led by Barts Cancer Institute (BCI), Queen Mary University of London, reveals novel insights into the role of the tumour […]
Read more27th February 2020
An immune therapy for the most aggressive form of breast cancer can substantially reduce the risk of the disease returning, according to a clinical trial led by Professor Peter Schmid of Barts Cancer Institute, Queen Mary University of London.
Read more12th December 2019
The Queen Mary University of London professor leading an international breast cancer study says anastrozole – rather than tamoxifen – should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.
Read more3rd October 2019
A lifetime model evaluating the financial, health and social impact of multigene testing at diagnosis for all breast cancer patients was found to save lives and be extremely cost-effective for both UK and US health systems.
Read more30th September 2019
Results of an interim analysis from the KEYNOTE-522 trial have shown a treatment combination of immunotherapy plus chemotherapy to improve response rates in patients with early triple-negative breast cancer. Prof Peter Schmid presented the results at the ESMO Congress 2019 in Barcelona, Spain.
Read more13th September 2019
Researchers are calling for population-wide BRCA testing in the Jewish community after finding it to be more effective than current approaches, cost effective and to have a high satisfaction rate with those undergoing testing.
Read more